Linscomb & Williams, Inc. Abb Vie Inc. Transaction History

Linscomb & Williams, Inc.

$2.01 Billion
Q3 2024

A detailed history of Linscomb & Williams, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Linscomb & Williams, Inc. holds 78,363 shares of ABBV stock, worth $13.4 Million. This represents 0.77% of its overall portfolio holdings.

Number of Shares

78,363

Previous 81,016 3.27%

Holding current value

$13.4 Million

Previous $13.9 Million 11.37%

% of portfolio

0.77%

Previous 0.72%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$163.84 - $199.33 $434,667 - $528,822	-2,653 Reduced 3.27%	78,363 $15.5 Million
Q2 2024 Aug 07, 2024	SELL	$154.79 - $180.76 $30,958 - $36,152	-200 Reduced 0.25%	81,016 $13.9 Million
Q1 2024 May 14, 2024	SELL	$159.82 - $182.1 $393,956 - $448,876	-2,465 Reduced 2.95%	81,216 $14.8 Million
Q4 2023 Feb 06, 2024	SELL	$137.6 - $154.97 $289,235 - $325,746	-2,102 Reduced 2.45%	83,681 $13 Million
Q3 2023 Oct 10, 2023	SELL	$133.59 - $154.65 $583,521 - $675,511	-4,368 Reduced 4.85%	85,783 $12.8 Million
Q2 2023 Aug 09, 2023	SELL	$132.51 - $164.9 $580,261 - $722,097	-4,379 Reduced 4.63%	90,151 $12.1 Million
Q1 2023 May 11, 2023	SELL	$144.61 - $166.54 $708,878 - $816,379	-4,902 Reduced 4.93%	94,530 $15.1 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $721,701 - $865,509	5,218 Added 5.54%	99,432 $16.1 Million
Q3 2022 Nov 09, 2022	SELL	$134.21 - $153.93 $64,957 - $74,502	-484 Reduced 0.51%	94,214 $12.6 Million
Q2 2022 Aug 15, 2022	SELL	$137.62 - $174.96 $933,338 - $1.19 Million	-6,782 Reduced 6.68%	94,698 $14.5 Million
Q1 2022 May 17, 2022	BUY	$131.98 - $163.75 $302,894 - $375,806	2,295 Added 2.31%	101,480 $16.5 Million
Q4 2021 Feb 10, 2022	BUY	$107.43 - $135.93 $99,050 - $125,327	922 Added 0.94%	99,185 $13.4 Million
Q3 2021 Nov 03, 2021	BUY	$106.4 - $120.78 $192,477 - $218,491	1,809 Added 1.88%	98,263 $10.6 Million
Q2 2021 Aug 10, 2021	BUY	$105.21 - $117.21 $282,909 - $315,177	2,689 Added 2.87%	96,454 $10.9 Million
Q1 2021 May 12, 2021	BUY	$102.3 - $112.62 $105,982 - $116,674	1,036 Added 1.12%	93,765 $10.1 Million
Q4 2020 Feb 11, 2021	BUY	$80.49 - $108.67 $174,904 - $236,139	2,173 Added 2.4%	92,729 $9.94 Million
Q3 2020 Nov 13, 2020	BUY	$85.91 - $100.83 $282,386 - $331,428	3,287 Added 3.77%	90,556 $7.93 Million
Q2 2020 Aug 11, 2020	BUY	$73.37 - $98.18 $820,570 - $1.1 Million	11,184 Added 14.7%	87,269 $8.57 Million
Q1 2020 May 11, 2020	BUY	$64.5 - $97.79 $298,441 - $452,474	4,627 Added 6.48%	76,085 $5.8 Million
Q4 2019 Feb 13, 2020	BUY	$72.13 - $90.25 $115,768 - $144,851	1,605 Added 2.3%	71,458 $6.33 Million
Q3 2019 Nov 08, 2019	BUY	$62.98 - $75.72 $370,637 - $445,612	5,885 Added 9.2%	69,853 $5.29 Million
Q2 2019 Aug 06, 2019	BUY	$65.7 - $83.98 $45,595 - $58,282	694 Added 1.1%	63,968 $4.65 Million
Q1 2019 May 09, 2019	BUY	$77.14 - $90.79 $129,903 - $152,890	1,684 Added 2.73%	63,274 $5.1 Million
Q4 2018 Feb 08, 2019	SELL	$77.85 - $96.01 $68,430 - $84,392	-879 Reduced 1.41%	61,590 $5.68 Million
Q3 2018 Nov 08, 2018	SELL	$88.91 - $98.84 $42,587 - $47,344	-479 Reduced 0.76%	62,469 $5.91 Million
Q2 2018 Aug 07, 2018	BUY	$89.78 - $106.23 $153,972 - $182,184	1,715 Added 2.8%	62,948 $5.83 Million
Q1 2018 May 04, 2018	SELL	$92.01 - $123.21 $60,266 - $80,702	-655 Reduced 1.06%	61,233 $5.8 Million
Q4 2017 Feb 02, 2018	SELL	$89.56 - $98.21 $102,725 - $112,646	-1,147 Reduced 1.82%	61,888 $5.99 Million
Q3 2017 Oct 27, 2017	BUY	$69.85 - $89.22 $4.4 Million - $5.62 Million	63,035	63,035 $5.6 Million

Others Institutions Holding ABBV

# of Institutions

3,863

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $302B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Linscomb & Williams, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Linscomb & Williams, Inc. with notifications on news.

Account

Linscomb & Williams, Inc. Abb Vie Inc. Transaction History